Janssen

Janssen, formally known as Johnson & Johnson Innovative Medicine (and formerly Janssen Pharmaceuticals), is a global pharmaceutical company founded in 1953 by Paul Janssen. It operates as a wholly-owned subsidiary of the American multinational corporation Johnson & Johnson. Janssen's main headquarters are located in Beerse, Belgium, with a significant presence and U.S. headquarters in Titusville, New Jersey. The company employs approximately 45,000 individuals worldwide.

Janssen focuses on the research, development, and manufacturing of medicines across a diverse range of therapeutic areas. Its major product lines address complex diseases within Oncology, Immunology, Neuroscience, Cardiopulmonary, Specialty Ophthalmology, Infectious Diseases & Vaccines, and Cardiovascular & Metabolism. Examples of their developments include treatments for conditions such as cancer, HIV/AIDS, schizophrenia, and inflammatory diseases. Beyond pharmaceuticals, a division called Janssen PMP provides solutions for crop management, antifouling, and material protection.

Based on the provided patent litigation data, Janssen maintains an assertive patent litigation posture, appearing as a plaintiff in one tracked case and as a defendant in zero cases. This indicates the company actively defends its intellectual property rights, a common practice for large pharmaceutical companies protecting their drug patents from potential infringement.

The most recent tracked case, Janssen et al. v. Bio-Thera, was filed on February 27, 2026, in the U.S. District Court for the District of Delaware, with Janssen as the plaintiff. This venue is frequently chosen for patent disputes, particularly in the pharmaceutical sector. The company's rebranding to Johnson & Johnson Innovative Medicine in September 2023 reflects its ongoing commitment to scientific innovation in medicine.